Literature DB >> 25114141

In vitro susceptibility of Plasmodium vivax to antimalarials in Colombia.

Diana Fernández1, César Segura1, Margarita Arboleda2, Giovanny Garavito3, Silvia Blair1, Adriana Pabón4.   

Abstract

The in vitro susceptibilities of 30 isolates of Plasmodium vivax to a number of antimalarials (chloroquine [CQ], mefloquine, amodiaquine, quinine, and artesunate [AS]) were evaluated. The isolates came from the region of Urabá in Colombia, in which malaria is endemic, and were evaluated by the schizont maturation test. The 50% inhibitory concentration (IC50) was 0.6 nM (95% confidence interval [CI], 0.3 to 1.0 nM) for artesunate, 8.5 nM (95% CI, 5.6 to 13.0 nM) for amodiaquine, 23.3 nM (95% CI, 12.4 to 44.1 nM) for chloroquine, 55.6 nM (95% CI, 36.8 to 84.1 nM) for mefloquine, and 115.3 nM (95% CI, 57.7 to 230.5 nM) for quinine. The isolates were classified according to whether the initial parasites were mature or immature trophozoites (Tfz). It was found that the IC50s for chloroquine and artesunate were significantly different in the two aforementioned groups (P < 0.001). The IC50s of CQ and AS were higher in the isolates from mature Tfz (CQ, 39.3 nM versus 17 nM; AS, 1.4 nM versus 0.3 nM), and 10% of the isolates showed lower susceptibilities to one of the antimalarial drugs, 13.3% to two antimalarial drugs, and 3.3% to more than three antimalarial drugs. It should be highlighted that despite the extensive use of chloroquine in Colombia, P. vivax continues to be susceptible to antimalarials. This is the first report, to our knowledge, showing in vitro susceptibilities of P. vivax isolates to antimalarials in Colombia.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25114141      PMCID: PMC4249416          DOI: 10.1128/AAC.03191-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Versatile Field's stain.

Authors:  A H Moody; S L Fleck
Journal:  J Clin Pathol       Date:  1985-07       Impact factor: 3.411

2.  [Ten years of chloroquine efficacy for uncomplicated Plasmodium vivax malaria treatment, Turbo, Antioquia, 2002 and 2011].

Authors:  Alexandra Ríos; Gonzalo Álvarez; Silvia Blair
Journal:  Biomedica       Date:  2013 Jul-Sep       Impact factor: 0.935

3.  Drug sensitivity of plasmodium falciparum. An in-vitro microtechnique.

Authors:  K H Rieckmann; G H Campbell; L J Sax; J E Mrema
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

4.  Therapeutic responses to different antimalarial drugs in vivax malaria.

Authors:  S Pukrittayakamee; A Chantra; J A Simpson; S Vanijanonta; R Clemens; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand.

Authors:  Kesinee Chotivanich; Rachanee Udomsangpetch; Wirongrong Chierakul; Paul N Newton; Ronatrai Ruangveerayuth; Sasithon Pukrittayakamee; Sornchai Looareesuwan; Nicholas J White
Journal:  Am J Trop Med Hyg       Date:  2004-04       Impact factor: 2.345

6.  Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic.

Authors:  Bruce M Russell; Rachanee Udomsangpetch; Karl H Rieckmann; Barbara M Kotecka; Russell E Coleman; Jetsumon Sattabongkot
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

7.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique.

Authors:  R E Desjardins; C J Canfield; J D Haynes; J D Chulay
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

8.  Chloroquine sensitivity of isolates of Plasmodium falciparum adapted to in vitro culture.

Authors:  T Ponnudurai; A D Leeuwenberg; J H Meuwissen
Journal:  Trop Geogr Med       Date:  1981-03

9.  Chloroquine-resistant Plasmodium vivax malaria in Peru.

Authors:  Trenton K Ruebush; Jorge Zegarra; Javier Cairo; Ellen M Andersen; Michael Green; Dylan R Pillai; Wilmer Marquiño; María Huilca; Ernesto Arévalo; Coralith Garcia; Lely Solary; Kevin C Kain
Journal:  Am J Trop Med Hyg       Date:  2003-11       Impact factor: 2.345

10.  An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine.

Authors:  Oumaporn Tasanor; Harald Noedl; Kesara Na-Bangchang; Kanungnit Congpuong; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Acta Trop       Date:  2002-07       Impact factor: 3.112

View more
  7 in total

1.  Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil.

Authors:  Simone Ladeia-Andrade; Maria José Menezes; Taís Nóbrega de Sousa; Ana Carolina R Silvino; Jaques F de Carvalho; Laís C Salla; Odaílton A Nery; Gladson N P de Melo; Rodrigo M Corder; Priscila T Rodrigues; Marcelo U Ferreira
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Chloroquine-Primaquine Therapeutic Efficacy, Safety, and Plasma Levels in Patients with Uncomplicated Plasmodium vivax Malaria in a Colombian Pacific Region.

Authors:  Esteban Mesa-Echeverry; Mayra Niebles-Bolívar; Alberto Tobón-Castaño
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

3.  Promising approach to reducing Malaria transmission by ivermectin: Sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi.

Authors:  Yudi T Pinilla; Stefanie C P Lopes; Vanderson S Sampaio; Francys S Andrade; Gisely C Melo; Alessandra S Orfanó; Nágila F C Secundino; Maria G V B Guerra; Marcus V G Lacerda; Kevin C Kobylinski; Karin S Escobedo-Vargas; Victor M López-Sifuentes; Craig A Stoops; G Christian Baldeviano; Joel Tarning; Gissella M Vasquez; Paulo F P Pimenta; Wuelton M Monteiro
Journal:  PLoS Negl Trop Dis       Date:  2018-02-14

4.  Molecular Surveillance and Ex Vivo Drug Susceptibilities of Plasmodium vivax Isolates From the China-Myanmar Border.

Authors:  Weilin Zeng; Hui Zhao; Wei Zhao; Qi Yang; Xinxin Li; Xiaosong Li; Mengxi Duan; Xun Wang; Cuiying Li; Zheng Xiang; Xi Chen; Liwang Cui; Zhaoqing Yang
Journal:  Front Cell Infect Microbiol       Date:  2021-11-01       Impact factor: 5.293

5.  Simultaneous detection of Plasmodium vivax dhfr, dhps, mdr1 and crt-o resistance-associated mutations in the Colombian Amazonian region.

Authors:  Juan Ricardo Cubides; Paola Andrea Camargo-Ayala; Carlos Hernando Niño; Diego Garzón-Ospina; Anggie Ortega-Ortegón; Estefany Ospina-Cantillo; María Fernanda Orduz-Durán; Manuel Elkin Patarroyo; Manuel Alfonso Patarroyo
Journal:  Malar J       Date:  2018-03-27       Impact factor: 2.979

6.  Ex vivo susceptibilities of Plasmodium vivax isolates from the China-Myanmar border to antimalarial drugs and association with polymorphisms in Pvmdr1 and Pvcrt-o genes.

Authors:  Jiangyan Li; Jie Zhang; Qian Li; Yue Hu; Yonghua Ruan; Zhiyong Tao; Hui Xia; Jichen Qiao; Lingwen Meng; Weilin Zeng; Cuiying Li; Xi He; Luyi Zhao; Faiza A Siddiqui; Jun Miao; Zhaoqing Yang; Qiang Fang; Liwang Cui
Journal:  PLoS Negl Trop Dis       Date:  2020-06-12

7.  Daily rhythms of both host and parasite affect antimalarial drug efficacy.

Authors:  Alíz T Y Owolabi; Sarah E Reece; Petra Schneider
Journal:  Evol Med Public Health       Date:  2021-04-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.